Paraoxonases: Structure, gene polymorphism & role in coronary artery disease

Indian Journal of Medical Research

Volumn 130, Issue 4, 2009, Pages 361-368

  Gupta, Nidhi ^a   Gill, Kirandip ^a   Singh, Surjit ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Atherosclerosis; Coronary artery disease; Paraoxonases; Polymorphism

Indexed keywords

APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; ARYLDIALKYLPHOSPHATASE 3; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; AMINO ACID SUBSTITUTION; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; CHROMOSOME 7Q; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; LIPID OXIDATION; NONHUMAN; PROMOTER REGION; PROTEIN STRUCTURE; REVIEW;

ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; ISOENZYMES; POLYMORPHISM, GENETIC;

EID: 71449093018     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Tunstall-Pedoe H, Kuulasma K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
2. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488-500.
3. Malhotra P, Kumar R, Kumari S, Singh MM. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347: 1835.
4. [No author listed]. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel II). Circulation 1994; 89: 1333-445.
5. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997; 28: 83-7.
6. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 (Suppl): S11-20.
7. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, et al. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 2007; 37: 715-23.
8. Watson AD, Navab M, Ham SY, Sevanian A, Prescott SM, Staffori DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-82.
9. Klimov AN, Nikiforova AA, Pleskov VM, Kuz'min AA, Kalashnikova NN. Protective effect of high density lipoproteins, their subfractions and lecithin-cholesterol-acyltransferases on the peroxidation modification of low density lipoproteins. Biokhimiia 1989; 54: 118-23.
10. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease:are activity and concentration are more important than genotype? Arterio Scler Thromb Vasc Biol 2001; 21: 1451-7.
11. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004; 37: 1317-23.
12. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002; 13: 357-62.
13. Singh S, Venketesh S, Verma JS, Verma M, Lellamma CO, Goel RC. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus. Indian J Med Res 2007; 125: 783-7.
14. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-47.
15. Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik DS. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci USA 2004; 101: 482-7.
16. Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, et al. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact 1993; 87: 35-48.
17. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991; 30: 10141-9.
18. Rowles J, Scherer SW, Xi T, Majer M, Nickle DC, Rommens JM, et al. Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human. J Biol Chem 1996; 271: 22376-82.
19. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004; 11: 412-9.
20. Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 2004; 22: 163-8.
21. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-6.
22. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000; 49: 1390-3.
23. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 2214-25.
24. Moren X, Deakin S, Liu ML, Taskinen MR, James RW. HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res 2008; 49: 1246-53.
25. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334-6.
26. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.
27. Oliveira SA, Mansur AP, Ribeiro CC, Ramires JA, Annichino-Bizzacchi JM. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2004; 94: 73-7.
28. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997; 17: 2935-9.
29. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998; 141: 259-64.
30. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol 1998; 18: 1611-6.
31. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004; 363: 689-95.
32. Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000; 152: 421-31.
33. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong C E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001; 11: 77-84.
34. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20: 516-21.
35. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001; 68: 1428-36.
36. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 2004; 61: 351-6.
37. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC. Promoter polymorphism T (-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000; 49: 1390-3.
38. Deakin S, Leviev I, Brulhart Meynet MC, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position -107, implicating the Sp1 transcription factor. Biochem J 2003; 372: 643-9.
39. Oaki F, Ikeda Y, Suehiro T, Ota K, Tsuzura S, Arii K, et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 2004; 176: 279-87.
40. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Fontana L, Castaldo M, et al. Association between serum paraoxonase (PON 1) gene promoter T(-107)C polymorphism, PON 1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 2004; 39: 1089-94.
41. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Castaldo M, Fontana L, et al. The paraoxonase promoter polymorphism (-107) T > C is not associated with carotid intima media thickness in Sicilian hypercholesterolemic patients. Clin Biochem 2004; 37: 388-94.
42. Najafi M, Gohari LH, Firoozrai M. Paraoxonase-1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res 2009; 123: 503-10.
43. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
44. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-90.
45. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM. Paraoxonase 1 overexpression in mice and its effect on high- density lipoproteins. Biochem Biophys Res Commun 2002; 290: 921-7.
46. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002; 13: 357-62.
47. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 1465-71.
48. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23: 2083-9.
49. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000; 150: 295-8.
50. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998; 24: 133-8.
51. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 2003; 73: 1393-400.
52. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229-35.
53. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38: 163-9.
54. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G, et al. Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002; 132: 3012-7.
55. Van Himbergen TM, Roest M, de Graaf J, Jansen EH, Hattori H, Kastelein JJ, et al. Indications that paraoxonase- 1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005; 46: 445-51.
56. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22: 1329-33.
57. Ferre N, Camps J, Fernandez-Ballart J, Arija V, Murphy MM, Ceruelo S, et al. Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in the general population. Clin Chem 2003; 49: 1491-7.
58. Van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet- controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999; 147: 405-10.
59. Sierksma A, van der Gaag MS, van Tol A, James RW, Hendriks HF. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 2002; 26: 1430-5.
60. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101: 2252-7.
61. Seres, I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004; 39: 59-66.
62. Senti M, Tomas M, Vila J, Marrugat J, Elosua R, Sala J, et al. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study. Atherosclerosis 2001; 156: 443-9.
63. Marsillach J, Ferre N, Vila MC, Lligň A, Mackness B, Mackness M, et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem 2007; 40: 645-50.
64. Ferre N, Marsillach J, Camps J, Rull A, Coll B, Tous M, et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis-C virus infection. Clin Chim Acta 2005; 361: 206-10.
65. Parra S, Alonso-Viaverde C, Coll B, Ferré N, Marsillach J, Aragones G, et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007; 194: 175-81.
66. Saeed M, Siddique N, Hung WY, Usacheva E, Liu E, Sufit RL, et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 2006; 67: 771-6.
67. Murphy MM, Vilella E, Ceruelo S, Figuera L, Sanchez M, Camps J, et al. The MTHFR C6 77T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 2002; 48: 372-5.
68. Leus FR, Zwart M, Kastelein JJ, Voorbij HA. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 2001; 154: 641-9.
69. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276: 44444-9.
70. Hong SH, Song J, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 2001; 34: 475-81.
71. Pan JP, Lai ST, Chiang SC, Chou SC, Chiang AN. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65: 415-21.
72. Martinelli N, Girelli D, Olivieri O, Stranieri C, Trabetti E, Pizzolo F, et al. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 2004; 34: 14-20.
73. Shiner M, Fuhrman B, Aviram M. Paraoxonase 2 (PON2) expression is upregulated via a reduced nicotinamide- adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocyte differentiation into macrophages. Free Radic Biol Med 2004; 37: 2052-63.
74. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275: 33435-42.
75. Harel M, Brumshtein B, Meged R, Dvir H, Ravelli RB, McCarthy A, et al. 3-D structure of serum paraoxonase1 sheds light on its activity, stability, solubility and crystallizability. Arh Hig Rada Toksikol 2007; 58: 347-53.